Source: EMA
Area: News
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product aflibercept (Eylea), 40 mg/mL solution for injection, intended for the treatment of neovascular (wet) age-related macular degeneration (AMD).
Aflibercept, an antineovascularisation agent, acts by binding and inhibiting VEGF-A (Vascular endothelial growth factor-A). A pharmacovigilance plan for Eylea will be implemented as part of the marketing authorisation.
Detailed recommendations for the use of this (Read more...)
Uncategorized